AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NEW YORK -- The asthma drug salmeterol does not appear to be a major human teratogen, Dr. Kenneth Lyons Jones reported at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.
Data are preliminary, however. Researchers with the multicenter Organization of Teratology Information Services (OTIS) are seeking more asthmatic pregnant women for a prospective study called the Asthma Medications and Pregnancy Project, supported by Aventis Pharmaceuticals Inc.
Of approximately 900 women enrolled in the study before 20 weeks' gestation, 125 had been exposed to salmeterol at some point during pregnancy: 88% had used the long-acting [beta]-agonist during the first trimester, and 77% continued to use it into the third trimester.
Pregnancy outcomes in these women were compared with those of 91 asthmatic pregnant women who used only short-acting [beta]-agonists and with 115 nonasthmatic pregnant women.
Maternal characteristics, including age, ethnicity, pregnancy history, smoking status, and previous therapeutic and elective abortions, did not differ among the three groups studied, said Dr. Jones, who is chief of dysmorphology/teratology and professor of pediatrics at the University of ...
Source: HighBeam Research, Salmeterol does not appear to be teratogenic. (Preliminary Data).